The occurrence of drug intolerance (DI) after an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) is an important reason for quitting treatment. Nevertheless, the association between DI and major cardiac and cerebrovascular events (MACCE) is poorly reported in the literature, therefore, we analysed potential relationship between DI and MACCE (a composite of ACS, PCI, heart failure, and stroke) during follow-up. 
Introduction
Patients affected by acute coronary syndrome (ACS) or treated by coronary revascularization procedure are at risk for subsequent cardiovascular adverse events during follow-up. 1 The use of drugs with prognostic value such as antiplatelet drugs, angiotensin-converting enzyme (ACE) inhibitors, statins (ST), and beta-blockers (BB) in association with an appropriate rehabilitation follow-up programme are measures that can reduce the onset of cardiovascular adverse events and reduce mortality. low adherence to recommended therapy have a poor outcome and that adherence outcome benefits are mediated by drug effects. 2 Reduced adherence to prescribed therapy is a frequent phenomenon with multifactorial genesis 3 with both psycho-social, 4 cultural, 5 and largely biological components. These latter are manifested primarily as drug intolerance (DI) and may involve prognostic therapy such as ST, 6, 7 ACE inhibitors, 8 and BB. 9 The occurrence of DI to recommended therapy after an ACS or coronary revascularization is frequent, however, is a poorly investigated cause of quitting treatment. 3 Moreover, the association between DI and major cardiac and cerebrovascular events (MACCE) is poorly reported in the literature. Therefore, we analysed the occurrence and relationship between DI and MACCE in a prospective cohort of patients who underwent a dedicated cardiac rehabilitation (CR) programme after discharge for planned coronary revascularization or ACS.
Methods

Study population
In this study, we analysed clinical and instrumental characteristics and outcomes of patients who were consecutively discharged from the Cardiovascular Department of the University Hospital of Trieste, Italy, after ST-elevation myocardial infarction (STEMI), Non-ST-elevation myocardial infarction (NSTEMI), coronary artery bypass grafting (CABG) surgery with or without valve surgery, or planned percutaneous coronary intervention (PCI), between 01 January 2014 and 31 December 2015. Per-protocol, all patients discharged from Cardiovascular Department were referred to CR Division with a scheduled visit reported on discharge letter. These patients were unselected, only those were not residents in the region or with severe non-cardiac comorbidities such as end-stage neoplasia, dementia, or immobilized patients, were excluded. According to guidelines, patients were enrolled in CR early after discharge: STEMI and CABG patients were convened to the first evaluation within 2 weeks, while NSTEMI and PCI in 4 weeks. At the first CR visit, the clinical profile of the patients, the risk factors, and comorbidities were evaluated and the CR programme was planned.
CR programme
The NSTEMI or PCI patients received clinical-instrumental evaluations until achievement of therapeutic and clinical targets, with scheduled visits, cycle-ergometer tests, and an echocardiogram. STEMI and CABG were also sent to a physical activity, consisting in a first part of 10 sessions of 45 min of cyclette training twice a week for 5 weeks, and a second part of 12 sessions of 45 min of gym training three times a week for 6 weeks. The mean duration of the CR programme for the whole population was 5.5 ± 2.5 months.
All groups received counselling about lifestyle during every visit and a nutritional meeting with the nutritionist was scheduled once a month during CR. Active smokers were assisted by the psychologist in a tailored programme to quit smoking. A psychologist was also dedicated to support patients that had difficulty accepting their disease.
Drug intolerance
DI was defined as the occurrence of a pharmacological side-effect leading the patient to withdraw the assumption of the drug or to reduce the recommended dosage. Resolution or significant improvement upon dose decrease or discontinuation of the suspected drug was necessary to meet the criteria of DI.
Patients with DI were defined as all patients who were found intolerant to one or more drugs during the CR programme. We collected DI for drugs necessary to achieve prognostic therapeutic goals (LDL below 70 mg/dL, heart rate below 70 b.p.m., blood pressure below 130/ 80 mmHg) such as ST, angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptors antagonists (ARBs), calcium channel blockers (CCB), BB, and ivabradine (IV). In addition, we also collected also intolerance to other drugs commonly used in patients affected by coronary artery disease (CAD) such as acetylsalicylic acid (ASA), P2Y12 inhibitors, vitamin K antagonists/Non-vitamin K antagonist oral anticoagulants (VKAs/NOACs), nitrates, ranolazine, and proton-pump inhibitors.
Particular attention was paid for common drug side effects as the occurrence of intolerable myalgia (muscle aches, pains, weakness, or cramps) for ST; dry cough, angioedema, hyperkalaemia for ACE-I and ARBs; flushing, peripheral oedema, symptomatic bradycardia, or atrioventricular block for CCB; bronchospasm, symptomatic bradycardia, or atrioventricular block for BB.
All patients with DI had a modified treatment: DI patients to ACE-I were switched to ARBs, DI patients to ST were switched to lower dosage or lower intensity ST, and, if guideline therapeutic targets were not reached, ezetimibe was added. DI patients to BB were switched to another type of BB and, if still not tolerated, ivabradine was started. ACE-I, BB, ASA, and ST were identified as prognostic drugs as they have been shown to improve outcome in patients affected by both CAD and ACS as shown by guidelines. [10] [11] [12] LDL cholesterol level, heart rate, and blood pressure data were recorded at the end of the CR programme.
Outcomes
The principal outcome evaluated was a composite of MACCE defined as hospital admission for ACS, elective percutaneous coronary angioplasty (PCI), heart failure, or stroke occurring during follow-up. Elective PCI was performed, only after proof of ischaemia at non-invasive tests of after positive fractional flow reserve when non-invasive tests were absent or inconclusive. Vital status and hospitalizations as well clinical outcomes were extracted from the Observational Cardiac Rehabilitation Division Registry.
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Statistical analysis
Continuous variables were expressed as mean ± standard deviation or as median with interquartile range (IQR) for continuous variables depending on the distribution shape. For continuous variables, differences between groups were compared using the Students' t-test or Mann-Whitney U test. Categorical variables were expressed as counts and percentages and compared by the v 2 test or Fisher's exact test, when appropriate.
Kaplan-Meier survival curves were estimated between DI and non-DI group and the log-rank test was performed. Univariable and multivariable logistic regression analysis was used to investigate the effect of DI on the principal outcome. A 'full-model' approach was used to estimate multivariable models, inserting all factors significantly related to outcome or clinically relevant.
Statistical analyses were performed using the IBM-SPSS version 21 (IBM Corp., Armonk, NY, USA) and the R statistical software version 3.4.0. The institutional ethical board approved the study, and informed consent was obtained under the institutional review board policies of hospital administration.
Results
During the study period, 891 unselected patients were referred to Cardiac Rehabilitation Division and enrolled. Three hundred and nine . . . . . . . . patients (34.7%) developed DI, 27% of them were female. Baseline characteristics of the population are shown in Table 1 . Baseline variables were similar between the DI group and the non-DI group. However, at the end of CR, the DI patients group had a higher LDL cholesterol mean value compared with the non-DI group (86 ± 31 vs. 79 ± 26, P = 0.005, respectively) and a lower frequency of LDL target levels (<70 mg/dL) (20.4% vs. 29.2%, P = 0.01, respectively).
The majority of patients exhibited DI to 1 drug, however, patients with multiple DI were detected ( Table 2) . ACE-I and ST followed by BB and CCB were the most frequent drugs which caused DI in 13.1%, 12.8%, 7.5%, and 5.5% of patients, respectively ( Table 2) . Figure 1 shows the percentages of class DI in patients with DI, and Figure 2 shows the percentages of DI to one or more drugs in patients with intolerance.
Outcome results
During a median follow-up of 18 (IQR 11-24) months, death occurred in 2.4% of patients and was similar between the DI group and the non-DI group. However, survival-free from MACCE was significantly different between the DI group and the non-DI group (log-rank P = 0.010, Figure 3 ). DI groups compared with the no-DI group had higher incidence of MACCE (14.1% vs. 8.1%, P = 0.007), ACS (5.2% vs. 1.2%, P = 0.001), and PCI (6.6% vs. 2.2%, P = 0.002) ( Table 3) .
At univariable analysis for MACCE, DI as well as DI to prognostic drug or to two drugs, DI to ACE-I and nitrates were associated with higher number of MACCE. Moreover, the baseline use of VKA/ Table 6) , testing the specific association of prognostic drugs to MACCE, only DI to ACE-I was independently associated with MACCE (OR 2.31, 95% CI 1.14-4.65; P = 0.019). No significant interaction was found between ACS group and DI on MACCE and between elective PCI group and DI on MACCE (see Supplementary material online, Table S1 ).
Discussion
This is the first study that evaluated the potential relationship between DI and clinical outcomes in patients discharged for ACS or planned coronary revascularization and who underwent a dedicated CR programme and tailored treatment. This study, performed on a large cohort of patients, presented important and novel findings: (i) through a dedicated registry, DI was frequently detected in realworld clinical setting presenting in about one-third of our population.
(ii) DI to one drug was independently associated to MACCE during follow-up, and DI to two or more drugs was independently associated to MACCE with an increased OR suggesting an higher risk of cardiovascular events in patients with multiple DIs. (iii) Evaluating specific drugs with demonstrated prognostic role, DI to ACE-inhibitors was independently associated to MACCE.
These findings are clinically relevant because a non-negligible proportion of patients with DI had an increased risk for recurrent cardiovascular events, despite a CR programme aimed to reach prognostic therapeutic goals, and this highlights how additional strategies are needed to reduce the risk of cardiovascular events in patients with DI.
A more aggressive secondary prevention medical therapy in DI patients seems advisable to compensate the absence of the protective effect of some non-tolerated drugs. Indeed, the DI patients included in our study presented significantly higher LDL levels compared with non-DI patients (86 ± 31 vs. 79 ± 26, respectively) despite the effort to optimize the therapy also with the addition of ezetimibe in case of ST intolerance. Whether DI to statin therapy is a phenomenon of mild relevance in randomized controlled trials, 15 is a welldocumented problem in real-life experience and is related to an increased risk for recurrent MI and CAD-related events. 16 About 13% of our population was intolerant to ST, a percentage that is in line with the American Medicare Beneficiaries, which presented ST intolerance in about 11%. 16 Differently from a recent real world study 16 in our analysis DI to ST was not associated to clinical outcomes, however, according with results of randomized trials, our follow-up may be too short to appreciate the real clinical benefit of ST in secondary prevention. 17 Conversely, ACE-I, the most frequent drugs which caused DI in our population, were independently associated to MACCE. It is well known that ACE-I reduce MI and revascularizations in patients with stable CAD and ACS. 18 Interestingly, in our study, DI patients to ACE-I were switched when possible to ARBs treatment and although ARBs in the context of STEMI were non-inferior to captopril in the VALIANT trial 19 and they certainly represent a good alternative to ACEIs, they are less validated than ACEIs for a protective role in ACS. 20 However, this finding should be considered as hypothesis generating and should be confirmed in larger studies.
The potential association of DI to nitrates and MACCE may reflect the role of a valuable agent as NT to control residual angina symptoms or angina due to progression of CAD. 21, 22 Indeed, a more frequent angina symptoms or early angina occurrence in patients intolerant to nitrates may have led to higher rate of re-admission for coronary angiographic control and/or elective PCI. Finally, the association of drug discontinuation or dose decrease and cardiovascular clinical outcomes has important clinical implications also outside the contest of DI, indeed, this remarks and reinforces the importance to maintain high drug adherence and the recommended dosage in patients with CAD. Indeed, every possible effort should be made to administer evidence-based doses of drugs to patients with appropriate clinical indications. Moreover, additional efforts to study the phenomenon of DI are critically important and should include development of alternative therapies for treating the substantial cardiovascular morbidity associated with this disorder.
Study limitations
The study has some limitations. A dedicated observational registry was built with the aim of collecting DI, however, DI judgement was left to physician discretion with the resolution or significant improvement upon drug dose decrease or discontinuation as one of the main criteria of DI. This approach reflects the absence of a standardized definition to identify patients with intolerance to the principal drug classes and also for drug classes with frequently reported intolerance. 23, 24 This however, highlights the need to work towards a Patients who complained about drug-related symptoms may be less adherent to a broad range of treatments, not just the suspected drug therapy causing intolerance and other unmeasured characteristics may distinguish patients with drug-associated intolerance.
The sample size of our study and the non-significance of certain findings are limitations of the study; moreover, the baseline angiographic disease severity was not evaluated.
Finally, whether DI is a direct cause of poor outcomes or just a marker of higher risk remains unknown due to the nature of the study, however, this study emphasizes the importance of reporting DI data for every patient for its potential prognostic role.
Conclusions
DI was frequently encountered in real-world clinical practice and was significantly associated with MACCE during follow-up. This study 
